Navigation Links
Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids

for both. These results were similar for both the modified intent-to-treat group and the group of patients that completed the study. A positive effect of reducing menstrual blood loss was a significant increase in hemoglobin in the Proellex treated group as a whole but particularly in those subjects with an abnormally low hemoglobin on study entry.

Women treated with 12.5mg and 25mg of Proellex for three months also experienced an overall highly statistically significant reduction in symptoms associated with uterine fibroids compared to the placebo group. After three months of treatment women on the 12.5 and 25 mg doses of Proellex had scores of 17.4 and 14.9 respectively compared to 40.1 for the placebo group. Other quality of life domains in the validated scale used in this trial included concern, activities, energy/mood, control, self-consciousness and sexual function. The high dose of Proellex achieved statistically significant improvements (p less than 0.05) versus placebo in all sub-domains.

Though not a primary endpoint, roughly 60% of the women in the study experienced pain as a symptom associated with uterine fibroids. When compared to baseline, women on Proellex experienced a statistically significant reduction in McGill pain scores for both the 25mg and 12.5mg dose. Of the women that experienced pain at baseline, 44.4% of women on the 25mg dose and 29.2% of women on the 12.5 mg dose became pain free while on the drug compared to 18.2% of women on placebo.

The effects on fibroid size were also measured but due to potential site to site variability no consistent dose dependent effects were observed. A separate assessment by a single reader will be attempted at a later date using the source documents generated in the trial. Though this effect is not considered a primary endpoint, effects on fibroid size are of interest to practitioners. In future studies where size is an endpoint MRI's will be used.

After three months on treatmen
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
2. Repros Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism
3. Repros Reports That Proellex Has Demonstrated Superior Efficacy and Safety in Endometriosis When Compared to Standard of Drug Care
4. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
5. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
6. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
7. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
8. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
9. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
10. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
11. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
Post Your Comments:
(Date:1/15/2014)... the leading health care supply chain expertise, analytics and ... national contracts that expand its portfolio to provide hospital ... These include manufacturer product and service agreements, as well ... IT consulting support. New Novation agreements ...
(Date:1/15/2014)... Jan. 15, 2014 Massachusetts General Hospital (MGH), ... AMGN ) announced today that they have launched ... new therapeutic targets and develop novel therapies for ... affects millions worldwide. The MGH-Broad-Amgen collaboration brings together ...
(Date:1/15/2014)... 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will ... Journal of Drugs in Dermatology (JDD) at ... The event is January 17-20, 2014, at the Omni Orlando Resort ... The ODAC is a distinguished event that ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
(Date:7/11/2014)... TX (PRWEB) July 11, 2014 Plasma ... of blood products industry. Although the closure of 16 ... major disruption to domestic blood products market, the total ... 2.8% year on year and total lot release volume ... due to stock consumption, insufficient utilization of new plasma ...
(Date:7/11/2014)... Even the hot Texas sun won’t keep ... . The school had previously invested in a ... from APCPLAY, but recently asked for an innovative solution to ... Godley Elementary School chose a Rectangular Shade from APCPLAY as ... on their playground. The shade measures 24’W x 34’H ...
(Date:7/11/2014)... Based in Pearland, Prime Urgent Care has ... County and surrounding counties. Recently, it improved access to ... from Northbound Highway 288 and Feeder Road. , Prime ... get low-cost urgent care of high quality. Although low-cost ... that can match the quality service level of the ...
(Date:7/10/2014)... July 10, 2014 Fatigue, lack ... an increasing number of accidents in the workplace, ... Reboot. The articles highlight safety issues that contribute ... million accidents occur on the job annually, according ... continue to explore "preventable workplace accidents." , Safety ...
(Date:7/10/2014)... July 11, 2014 According to ... Market by Platforms (Land, Airborne, Naval), Application (Software ... & by Geography (North America, Asia-Pacific, Europe, the ... (2014-2019)", published by MarketsandMarkets, the market is estimated ... expected to register a CAGR of 5.56% to ...
Breaking Medicine News(10 mins):Health News:Chinese Blood Product Industry Report 2014-2017 Focuses Plasma Volume & Stations Says A New Research Available at ChinaMarketResearchReports.com 2Health News:Chinese Blood Product Industry Report 2014-2017 Focuses Plasma Volume & Stations Says A New Research Available at ChinaMarketResearchReports.com 3Health News:Chinese Blood Product Industry Report 2014-2017 Focuses Plasma Volume & Stations Says A New Research Available at ChinaMarketResearchReports.com 4Health News:Cool Fun Under the Texas Sun: Godley Elementary School Purchases Shade Structure from APCPLAY© 2Health News:Prime Urgent Care Announces New Access to the Clinic, Available from Northbound Highway 288 2Health News:Safety Reboot Magazine Focuses on: Why Extended Hours is Dangerous in the Workplace; Why Custodial Work Can be Dangerous; and Improving Safety for Roofers 2Health News:Safety Reboot Magazine Focuses on: Why Extended Hours is Dangerous in the Workplace; Why Custodial Work Can be Dangerous; and Improving Safety for Roofers 3Health News:Portable Communication Systems Market Projected to Reach $39.52 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Portable Communication Systems Market Projected to Reach $39.52 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Portable Communication Systems Market Projected to Reach $39.52 Billion by 2019 - New Report by MarketsandMarkets 4
... artemisinin yield from the herb Artemisia annua by specifying ... ,The two developments could bring down the ... Organization to treat malaria. Over 100 countries use it ... the drug chloroquine. ,A study, published in ...
... Legionnaires’ disease. // ,Jack Russell was admitted to ... of the bacteria Legionella pnuemophila, which causes the disease. ... It takes its name from the first known outbreak, which ... the Pennsylvania Department of the American Legion in 1976. ...
... of Pennsylvania School of Veterinary Medicine have derived uniparental ... eggs or two// sperm - and, for the first ... with healthy cells in adult mice. Their ... in an adult organ and could provide a less ...
... genes associated with the risk of developing Type II ... at risk a step closer. ,Researchers have ... that correspond to a risk of developing this life ... nearly 400,000 mutations in nearly 6,500 people. ...
... composer is just one of many blind people around the ... , Scientists working for the Doheny Eye ... a previous invention released in 2002; a prototype artificial retina. ... its successor, the Argus II Retinal Prosthesis System. ...
... come out with a device which is likely// to ... control issues. ,They have named this ... circuit in spinal cord which is responsible for the ... sustain continence. This device is extremely useful in patients ...
Cached Medicine News:Health News:Scientists Boost Production of Cheap Malaria Drugs 2Health News:Convict Felled by Legionnaires 2Health News:'single–parent' stem cells to replace adult mice organ 2Health News:'single–parent' stem cells to replace adult mice organ 3Health News:Genetic Test for Type II Diabetes Moves Closer 2Health News:Genetic Test for Type II Diabetes Moves Closer 3Health News:Bionic Eye may Restore Sight to the Blind 2Health News:Bladder Pacemaker For Incontinence 2Health News:Bladder Pacemaker For Incontinence 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: